Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Nov 01, 2022 10:25am
223 Views
Post# 35062832

$ 8

$ 8If SAMI proves out in the "field" and DIMI marches towards a FULL FDA approval ("when not if" per Seto)...

...I stand by my estimate that it will one day be a $ 2B USD asset.

But it will likely need to be in the hands of a major player that can, amoungst other things, leverage their patient clinics into home dialysis (the new paradigm for dialysis)

For example the new JV of Medtronics and DaVita is targeting $ 2B in Sales for home based and innovative care using some unknown hardware.  A one times Sales valuation (conservative - but you know me) would be $ 2B USD !

Fresenius a few years back, bought NxStage (and their recently approved FDA machine for home use) for $ 2B USD

Outset had a valuation of close to $ 2B USD a year or so ago  (for the then only other dialysis pump approved for home use). 

Spectral is potentially  sitting on a "game-changing" technology (ease of use, breaks down barriers to adoption in the home, etc.)

Oh and $ 2B USD / 350 M shares = approximately $ 8 /CAD

BUT...Spectral will need a well known partner to drive adoption, sales, etc.  So they may have to share some of the upside.  I'm OK with that...if it gets the job done and on the path to being worth $ 2B.

MM

PS Morale of the story... don't be stuckupatree and under appreciate the assets that you own
<< Previous
Bullboard Posts
Next >>